We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sends Warning Letter on GMPs to Ranbaxy Subsidiary Ohm
FDA Sends Warning Letter on GMPs to Ranbaxy Subsidiary Ohm
January 19, 2010
Ranbaxy Laboratories subsidiary Ohm Laboratories has received a warning letter for good manufacturing practice (GMP) violations at its facility for making oral solutions.